Core Viewpoint - The company has announced that its six respiratory pathogen nucleic acid testing kits have recently obtained EU CE IVDR certification, allowing for sales in EU countries and countries that recognize EU CE certification [1] Group 1 - The product is designed to work with the company's digital microfluidic Logilet Logicore detection system [1] - The testing process utilizes microfluidic chips to complete the entire workflow of nucleic acid extraction, amplification, and detection [1] - The kits enable precise detection of six respiratory pathogens, facilitating fully automated genetic testing [1]

Group 1 - The Deputy Mayor emphasizes the importance of implementing the spirit of the 20th Central Committee and the key speeches by General Secretary Xi Jinping, focusing on achieving annual goals and leveraging comparative advantages [1] - The company Out of the Door Innovation Technology specializes in generative artificial intelligence and voice interaction, with operations spanning multiple countries and regions [1] - The Deputy Mayor encourages the company to target cutting-edge technologies and niche markets, accelerating technological innovation and application to meet market demands [1] Group 2 - Novozymes Biotechnology Co., Ltd. is dedicated to protein science research and product development, having recently overcome several critical technologies in high-end enzymes and antigens [2] - The Deputy Mayor urges the company to deepen its focus on core technologies and utilize innovation platforms like artificial intelligence to enhance product development and drive innovation results [2] - BOE Technology Group has become a global leader in the semiconductor display field through years of innovation, with the Deputy Mayor visiting their Nanjing facility to discuss investment and development plans [2]

Core Viewpoint - The announcement from China Securities Index Co., Ltd. regarding the periodic adjustment of various indices, including the CSI 300, CSI 500, and CSI 1000, indicates significant changes in sample stocks, effective after market close on December 12, 2025 [1]. Group 1: Index Adjustments - The CSI 300 index will replace 11 sample stocks, the CSI 500 will replace 50, the CSI 1000 will replace 100, the CSI A50 will replace 4, the CSI A100 will replace 6, and the CSI A500 will replace 20 [1]. - Notably, NuoVivian (688105.SH) has been removed from the CSI 1000 index sample [2]. Group 2: NuoVivian Financial Performance - In 2024, NuoVivian reported a revenue of 1.378 billion yuan, a year-on-year increase of 7.15%, but a net loss attributable to shareholders of 18.09 million yuan, compared to a loss of 70.96 million yuan in the previous year [3]. - For the first three quarters of 2025, NuoVivian achieved a revenue of 0.952 billion yuan, a year-on-year decrease of 3.40%, with a net profit of 6.62 million yuan, down 63.57% [4]. - The net cash flow from operating activities for NuoVivian was 64.55 million yuan in the first three quarters of 2025, compared to a negative cash flow of 99.99 million yuan in the same period last year [4]. Group 3: IPO and Fundraising - NuoVivian was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on November 15, 2021, with an issuance of 40.01 million shares at a price of 55.00 yuan per share, raising a total of 2.201 billion yuan [4]. - The net amount raised after deducting issuance costs was 2.109 billion yuan, exceeding the original plan by 907 million yuan [4]. - The total issuance costs amounted to 91.38 million yuan, with the lead underwriter, Huatai United Securities, receiving 72.64 million yuan in fees [4].

中国经济网北京12月9日讯中证指数有限公司2025年11月28日发布关于沪深300、中证500、中证1000、中证A500等指数 定期调整结果的公告。根据指数规则，经指数专家委员会审议，中证指数有限公司决定调整沪深300、中证500、中证 1000、中证A50、中证A100、中证A500等指数样本，于2025年12月12日收市后生效。其中沪深300指数更换11只样本， 中证500指数更换50只样本，中证1000指数更换100只样本，中证A50指数更换4只样本，中证A100指数更换6只样本， 中证A500指数更换20只样本。 调整结果显示，诺唯赞(688105.SH)被调出中证1000指数样本。 | | 调出名单 | | 调入名单 | | --- | --- | --- | --- | | 605222 | 起帆电缆 | 603887 | 城地香江 | | 605368 | 蓝天燃气 | 605099 | 共创草坪 | | 605577 | 龙版传媒 | 602118 | 力鼎光电 | | 688018 | 乐鑫科技 | 602198 | 安德利 | | 688019 | 安集科技 | 688032 | 禾迈股 ...

Industry Overview - Collagen masks are mainstream skincare products focused on anti-aging and repair, utilizing collagen as the core ingredient along with auxiliary components to achieve hydration and skin barrier repair [1][2] - The Chinese mask industry is expected to reach a market size of 72.986 billion yuan in 2024, entering a period of adjustment and transformation, facing growth slowdown and intensified competition [1][6] - The collagen market is experiencing explosive growth, with a compound annual growth rate (CAGR) of 41.9% from 2020 to 2023, and retail scale expected to exceed 269.5 billion yuan by 2030 [1][7] Market Dynamics - The market structure in China shows that sheet masks remain dominant, while cream masks are rapidly growing, focusing on hydration and repair needs [1][7] - The competitive landscape features local leaders dominating, niche players breaking through, and international brands penetrating the market, with a clear price gradient and significant differentiation between high, medium, and low-end markets [1][8] Industry Chain - The upstream of the collagen mask industry primarily uses animal-derived collagen, while recombinant collagen is rapidly developing due to its high purity and compatibility with mask formulations [6][10] - The manufacturing process involves various technologies to convert raw materials into different forms and functions of mask products, with sales channels dominated by online e-commerce and deepening offline professional channels [6][10] Current Development - The Chinese mask industry is transitioning into a phase of deep integration after rapid growth, with three emerging drivers leading market changes: consumption upgrades, male skincare market expansion, and personalized demand fostering innovative scenarios [6][7] - The market size is projected to steadily grow to 76.79 billion yuan by 2025 and potentially exceed 146.42 billion yuan by 2030, indicating robust long-term growth prospects [6][7] Key Players - Major companies in the collagen mask industry include Juzi Biotechnology, Huaxi Biotechnology, and Marubi Biotechnology, leveraging differentiated technologies and channel advantages to lead the market [2][10] - The industry is characterized by a multi-faceted competitive ecosystem, with local leaders, niche players, and international brands all contributing to the market dynamics [10] Future Trends - The industry is expected to advance towards high-end technology, refined products, and standardized ecosystems, with a focus on cross-disciplinary technology integration and precise formulations [10][12] - Regulatory tightening is anticipated to accelerate the elimination of smaller brands, increasing market concentration, while leading companies will strengthen their market positions through R&D innovation and global expansion [10][14]

证券代码：688105 证券简称：诺唯赞 公告编号：2025-055 南京诺唯赞生物科技股份有限公司2025年第二次临时股东会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的 真实性、准确性和完整性依法承担法律责任。 重要内容提示： ● 本次会议是否有被否决议案：无 一、会议召开和出席情况 （一）股东会召开的时间：2025年12月5日 （二）股东会召开的地点：南京市栖霞区科创路红枫科技园D2栋1楼报告厅 （三）出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及其持有表决权数量的情 况： 表决情况： ■ ■ （四）表决方式是否符合《公司法》及公司章程的规定，股东会主持情况等。 本次股东会由公司董事会召集，董事长曹林先生主持，会议采用现场投票和网络投票相结合的表决方 式。本次股东会的召集和召开程序、出席会议人员资格和召集人资格、会议表决方式和表决结果均符合 《中华人民共和国公司法》及《公司章程》的规定。 （五）公司董事和董事会秘书的列席情况 1、公司在任董事9人，列席8人，独立董事蔡江南先生因公请假，未列席本次会议。 2、董事会秘书黄金先生列席本次会 ...

北京市天元律师事务所 京天股字（2025）第 723 号 致：南京诺唯赞生物科技股份有限公司 南京诺唯赞生物科技股份有限公司（以下简称"公司"）2025 年第二次临时股 东会（以下简称"本次股东会"）采用现场投票与网络投票相结合的方式召开，现场 会议于 2025 年 12 月 5 日下午 15:00 在南京市栖霞区科创路红枫科技园 D2 栋公司 1 楼报告厅召开。北京市天元律师事务所（以下简称"本所"）接受公司聘任，指派 本所律师参加本次股东会现场会议，并根据《中华人民共和国公司法》、《中华人民 共和国证券法》（以下简称"《证券法》"）、《上市公司股东会规则》（以下简称"《股 东会规则》"）以及《南京诺唯赞生物科技股份有限公司章程》（以下简称"《公司 章程》"）等有关规定，就本次股东会的召集、召开程序、出席会议人员的资格、 召集人资格、会议表决程序和表决结果等有关事宜出具本法律意见。 为出具本法律意见，本所律师审查了《南京诺唯赞生物科技股份有限公司第二 届董事会第二十次会议决议公告》、《南京诺唯赞生物科技股份有限公司关于召开 2025 年第二次临时股东会的通知》（以下简称"《召开股东会通知》"）以及本所律 师 ...

证券代码：688105 证券简称：诺唯赞 公告编号：2025-055 南京诺唯赞生物科技股份有限公司 2025年第二次临时股东会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 | 1、出席会议的股东和代理人人数 | 71 | | --- | --- | | 普通股股东人数 | 71 | | 2、出席会议的股东所持有的表决权数量 | 232,121,546 | | 普通股股东所持有表决权数量 | 232,121,546 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的 | 58.3797 | | 比例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 58.3797 | 2、 董事会秘书黄金先生列席本次会议。 （四） 表决方式是否符合《公司法》及公司章程的规定，股东会主持情况等。 本次股东会由公司董事会召集，董事长曹林先生主持，会议采用现场投票和 网络投票相结合的表决方式。本次股东会的召集和召开程序、出席会 ...

Core Points - The stock price of NuoVivian has decreased by 2.07% to 21.76 CNY per share, with a total market capitalization of 8.655 billion CNY [1] - The company has experienced a year-to-date stock price decline of 1.18%, with a 4.27% drop over the last five trading days [1] - NuoVivian's main business includes the research and development of functional proteins and high molecular organic materials, with a revenue composition of 81.86% from biological reagents [1] Financial Performance - As of September 30, NuoVivian reported a total of 9,447 shareholders, an increase of 9.90% from the previous period [2] - For the period from January to September 2025, the company achieved a revenue of 952 million CNY, a year-on-year decrease of 3.40% [2] - The net profit attributable to the parent company was 6.6152 million CNY, reflecting a significant year-on-year decrease of 63.57% [2] Dividend Information - Since its A-share listing, NuoVivian has distributed a total of 731 million CNY in dividends, with 611 million CNY distributed over the past three years [3]

证券代码：688105 证券简称：诺唯赞 公告编号：2025-054 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2025/6/20 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 2025 6 6 月 | 年 | 月 | 19 | 日~2026 | 年 | 18 日 | | 预计回购金额 | 500万元~1,000万元 | | | | | | | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | | | | | | | □用于转换公司可转债 | | | | | | | | | □为维护公司价值及股东权益 | | | | | | | | 累计已回购股数 | 12.77万股 | | | | | | | | 累计已回购股数占总股本比例 | 0.03% | | | | | | | | 累计已回购金额 | 299.97万元 | | | | | | | | 实 ...